Polygenic score
Influential genes: PTCSC2,NRG1,DIRC3
PTCSC2 is a gene that has been linked to an increased risk of developing papillary thyroid carcinoma (PTC), the most common type of thyroid cancer.
NRG1 plays a role in the growth and development of multiple organ systems. An association of NRG1 gene and papillary thyroid cancer has been reported in scientific literature.
The DIRC3 gene has been shown to be downregulated in differentiated thyroid carcinomas (DTC). Moreover, its high expression in tumors may reduce the risk of tumor recurrence.
Thyroid cancer is an abnormal growth of the cells originating in the thyroid gland, a gland producing hormones that regulate the body's metabolism. As thyroid cancer grows, it can cause voice changes and difficulty swallowing. One of the main risk factors is exposure to ionizing radiation and pre-existing thyroid disease.
Thyroid cancer is a disease in which malignant cells form in the tissues of the thyroid gland - a small gland located on our neck producing hormones that regulate the body's metabolism. There are four different types of thyroid cancer, including papillary carcinoma, follicular carcinoma, medullary thyroid carcinoma, and anaplastic carcinoma - all of which have an individual prognosis, affect different cells and target different groups of patients:
Over the last decades, the incidence of thyroid cancer has kept rising, mainly due to the increase in the usage of ultrasound examinations leading to the detection of even small tumors. A higher increase is observed in the more developed countries compared to less developed countries - however, the mortality rates are equal. The incidence also differs in sex and region, affecting three times more women than men and most affected countries in Europe being Lithuania, Italy, and Austria.[2] Thyroid cancer is nowadays the most common endocrine cancer and represents the seventh most common malignancy in women - but it is not even among the 15 common cancers in men.[3]
The exact reason for the malignant growth of the cells is unfortunately unknown, but certain risk factors can increase the risk of developing the disease.
Although their influence is significantly lower, there are even more risk factors, including thyroid nodules, high BMI, lifestyle, diet, iodine deficiency, or autoimmune diseases.[4]
Recent progress in genome sequencing has offered a better understanding of the molecular mechanisms of thyroid cancer (TC). Familial forms of medullary thyroid cancer (MTC) have been described, but a person with an affected first degree relative with non-medullary thyroid cancer has a 4x to 10x higher risk of developing the disease as well.[11,12]
The molecular mechanisms of TC involve disruption of important cellular signaling pathways (a series of chemical reactions that result in the activation/deactivation of certain cellular functions: e.g. MAPK and PI3K/AKT).[11]
Mutations in the following genes have been described to cause TC: RET, RAS, P13K/AKT, BRAF, and TERT. Many research groups described an association of BRAF variant p.V600E (amino acid valine is replaced with glutamic acid on position 600) with poor outcomes of papillary thyroid cancer (PTC), including increased risk of recurrence and treatment failures. Observed hTERT mutations have a significantly higher prevalence in aggressive TC tumors and mutations of the BRAF, RAS, or RET genes are found in up to 70% of PTC cases. Overall, cancer-promoting mutations are identified in more than 90% of patients.[12,13]
Here in Macromo, polygenic risk scores are used to determine the genetic risk. The polygenic risk score (PRS) is an estimate of the probability that an individual carries a given trait based on genetics, without considering environmental factors. Variants across their genome are summed and weighted according to their effect on the disease or trait.
It's quite common for patients with thyroid cancer to experience only mild symptoms or none. The changes that might indicate the disease include:
If you experience any of these symptoms, don't hesitate to contact your doctor. But don't panic; in many cases, the causes of those symptoms are non-cancerous medical conditions.[5] Lumps in the thyroid gland are very common, and in 95% bening - it's estimated that more than half of the population will have at least one thyroid nodule by the age of 60.[6]
If any present symptoms increase the suspicion of thyroid cancer, your doctor will do a thorough anamnesis, physical examination and might indicate further steps. A blood test, called a thyroid function test, is used to assess thyroid hormone levels. Abnormal thyroid levels usually indicate issues other than cancer, such as hypo or hyperfunctioning thyroid gland. To find suspicious areas and their characteristics, various imaging methods are used. One of the most used methods is ultrasound, especially because it's quick, cheap, and usually readily available. Ultrasound uses high-frequency sound waves and creates a real-time image of the inside of your body. A biopsy must be performed to assess whether a thyroid lump is cancerous. During biopsy, a small amount of tissue is extracted with a needle and analyzed in the lab. This histopathologic examination is the only method able to confirm the diagnosis, sometimes the biopsy is only obtained during the surgery to decide about the next step intraoperatively.[7]
Thyroid cancer therapy highly depends on the type of cancer and how much it has spread. A widespread method is a surgery called a thyroidectomy, in which the thyroid gland or its parts are surgically removed. Another commonly used procedure is radioactive iodine treatment, in which a radioactive substance is swallowed in the form of a drink or a capsule and absorbed in the gut. It then travels to the thyroid gland, and attacks cancerous cells locally. Iodine is a main component in the synthesis of thyroid hormones, which is why the therapy works very well and only affects the gland while sparing the body. Some newer methods include thyroid hormone therapy and targeted cancer drugs that directly target the cancer cells and try to minimize the damage to healthy cells. If other treatments aren't successful, external radiotherapy might be used - a method in which radioactive beams try to damage the cancer cells from a machine outside the body. Chemotherapy isn't commonly used for thyroid cancer, only if cancer has spread or returned and can't be sufficiently treated by the other treatment options.[8]
As in all cancers, thyroid cancer can't be fully prevented, and most of the patients didn't have any known risk factors causing the development of the disease. But as we already know, proven risk factors exist, and it's therefore always beneficial to limit exposure to them to the minimum.
On the opposite of the incidence of thyroid cancer, mortality rates have decreased in Europe over time. Thyroid cancer has overall the highest survival rate and the best prognosis of all malignant tumors, except for some rare histological types (such as the previously mentioned anaplastic thyroid carcinoma, which is one of the most aggressive cancers in humans). The 5-year relative survival rate in Europe ranges from 80-90%. Due to the increased detection and better diagnostics, many thyroid tumors are found in the initial stages and might be effectively treated.[2]
Get the guidelines for a healthier and longer life. With Macromo tests, you'll learn your health risks and how to prevent them.
Continue to Shop[1] Medullary Thyroid Cancer - National Cancer Institute. www.cancer.gov. Published February 27, 2019. https://www.cancer.gov/pediatric-adult-rare-tumor/rare-tumors/rare-endocrine-tumor/medullary-thyroid-cancer
[2] European Network of Cancer Registries Thyroid cancer (TC) Factsheet Gender differences in Europe in 2012* Estimated incidence and mortality 4 Regional differences in Europe in 2012 Estimated incidence and mortality 4. (2017). www.encr.eu
[3] Rahbari R, Zhang L, Kebebew E. Thyroid cancer gender disparity. Future Oncol. 2010;6(11):1771-1779. doi:10.2217/fon.10.127
[4] Bogović Crnčić T, Ilić Tomaš M, Girotto N, Grbac Ivanković S. Risk Factors for Thyroid Cancer: What Do We Know So Far?. Acta Clin Croat. 2020;59(Suppl 1):66-72. doi:10.20471/acc.2020.59.s1.08
[5] Signs and Symptoms of Thyroid Cancer. (n.d.). Retrieved January 12, 2023, from https://www.cancer.org/cancer/thyroid-cancer/detection-diagnosis-staging/signs-symptoms.html
[6] Thyroid Nodules: When to Worry | Johns Hopkins Medicine. (n.d.). Retrieved January 12, 2023, from https://www.hopkinsmedicine.org/health/conditions-and-diseases/thyroid-nodules-when-to-worry
[7] Tests for Thyroid Cancer. (n.d.). Retrieved January 12, 2023, from https://www.cancer.org/cancer/thyroid-cancer/detection-diagnosis-staging/how-diagnosed.html
[8] Treatment options for thyroid cancer | Cancer Research UK. (n.d.). Retrieved January 12, 2023, from https://www.cancerresearchuk.org/about-cancer/thyroid-cancer/treatment/treatment-decisions
[9] Can Thyroid Cancer Be Prevented? (n.d.). Retrieved January 12, 2023, from https://www.cancer.org/cancer/thyroid-cancer/causes-risks-prevention/prevention.html
[10] Thyroid Cancer Prevention: Top 5 Things You Can Do. (n.d.). Retrieved January 12, 2023, from https://www.thyroidcancer.com/blog/thyroid-cancer-prevention-top-5-things-you-can-do
[11] Prete A, Borges de Souza P, Censi S, Muzza M, Nucci N, Sponziello M. Update on Fundamental Mechanisms of Thyroid Cancer. Front Endocrinol. 2020;11:102. doi:10.3389/fendo.2020.00102
[12] Younis E. Oncogenesis of Thyroid Cancer. Asian Pac J Cancer Prev APJCP. 2017;18(5):1191-1199. doi:10.22034/APJCP.2017.18.5.1191
[13] Abdullah MI, Junit SM, Ng KL, Jayapalan JJ, Karikalan B, Hashim OH. Papillary Thyroid Cancer: Genetic Alterations and Molecular Biomarker Investigations. Int J Med Sci. 2019;16(3):450-460. doi:10.7150/ijms.29935